TP53 and neoplasm: Combining compound C (a potent and selective AMPK inhibitor that suppressed autophagy) with topotecan in vivo showed a similar trend to that of CQ, with increasing topotecan-antitumor effects in HCT116 p53+/+ tumor cells but not in the p53−/− xenograft model [51].